biotechNew
Insilico Medicine
End-to-end AI drug discovery from target to clinic.
weight 0.0PaidLaunched 2026-06-07
💸 No earnings reported yet
What it is
A generative-AI biotech that took an idiopathic pulmonary fibrosis compound from target identification to Phase II in under 30 months, holding the sector's most credible end-to-end claim.
How AI plugs in
Generative deep-learning engines (PandaOmics for target discovery, Chemistry42 for molecule design) propose novel drug candidates end-to-end, taking programs from target to clinic without human-led screening.
★ Reviews
No reviews yet — be the first.Your rating